Loading clinical trials...
Loading clinical trials...
Persistence of Antibodies After Vaccination With a Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children and Safety and Immunogenicity of a Booster Dose at 68 Months Post-primary Vaccination
Conditions
Interventions
Nimenrix (GSK134612 vaccine)
Menjugate
Locations
24
France
GSK Investigational Site
Draguignan, France
GSK Investigational Site
Le Havre, France
GSK Investigational Site
Lingolsheim, France
GSK Investigational Site
Miribel, France
GSK Investigational Site
Nice, France
GSK Investigational Site
Paris, France
Start Date
January 3, 2011
Primary Completion Date
March 31, 2014
Completion Date
May 17, 2014
Last Updated
November 23, 2020
NCT07505836
NCT07505823
NCT04886154
NCT01939158
NCT02451514
NCT02946385
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions